Efficacy and Cardiovascular Safety of Thiazolidinediones.
Type 2 diabetes mellitus (T2DM) is characterized by a progressive beta cell dysfunction in the setting of peripheral insulin resistance. Insulin resistance in subjects with type 2 diabetes and metabolic syndrome is primarily caused by an ectopic fat accumulation in the liver and skeletal muscle. Insulin sensitizers are particularly important in the management of T2DM. Though thiazolidinediones (TZDs) are principally insulin sensitizers, they possess an ability to preserve pancreatic β-cell function and thereby exhibit durable glycemic control. Cardiovascular outcome trials (CVOTs) have shown that Glucagon-like-peptide 1 receptor agonists (GLP-1 RAs) and sodium glucose transporter-2 inhibitors (SGLT2i) have proven cardiovascular safety. In this era of CVOTs, drugs with proven cardiovascular (CV) safety are often preferred in patients with preexisting cardiovascular disease or at risk of cardiovascular disease. In this review, we will describe the three available drugs belonging to the TZD family, with special emphasis on their efficacy and CV safety.
['Raveendran|Arkiath Veettil|AV|', 'Fernandez|Cornelius James|CJ|', 'Jacob|Koshy|K|']
D002318:Cardiovascular Diseases D003924:Diabetes Mellitus, Type 2 D006801:Humans D007004:Hypoglycemic Agents D000077203:Sodium-Glucose Transporter 2 Inhibitors D045162:Thiazolidinediones
insulin resistance glycemic control cardiovascular disease Pioglitazone heart failure rosiglitazone